Bioreactor-based Drug Delivery Service

Your Trusted Bioreactor-based Drug Delivery Partner

Bioreactor-based drug delivery systems are at the forefront of the rapidly evolving field of nanotechnology. A bioreactor is a system that can produce a target substance through biochemical reactions or biotransformation using biological conditions including organisms, tissues, cells, and enzymes. With our extensive expertise in GlycoCLICK™ technology, CD BioGlyco has been providing our esteemed clients with reliable and credible GlycoCLICK™-based Drug Delivery Services for several years. Our cutting-edge bioreactor-based drug delivery service is designed to expedite your progress in drug discovery and development.

N-azidoacetyl-D-mannosamine (Ac₄ManNAz)-dibenzocyclooctyne (DBCO)-modified liposome drug delivery service
Using metabolic glycoengineering, we enable the biosynthesis of azido groups and their expression on the cell surface of tumors by injecting Ac₄ManNAz into tumor tissues. The biological fate and tumor distribution of DBCO-modified liposomes are altered by the strain-promoted alkyne-azide cycloaddition (SPAAC) reaction between the azide moiety and DBCO, improving their targeting efficiency.
Chitosan nanoparticles loaded with Ac₄ManNAz (Ac₄ManNAz-CNP)-modified nanoparticles (NP) drug delivery service
We perform a two-step in vivo tumor targeting strategy for nanoparticles via metabolic glycoengineering and click chemistry. First, intravenous injection of Ac₄ManNAz-CNP generated azide moieties on tumor tissues through site-specific metabolic glycoengineering. These azide moieties would enhance tumor targeting through copper-free click chemistry in vivo. Thus, a second round of drug-containing nanoparticles can deliver a large amount of drug.
Azido-sialic acid-bicyclo[6.1.0]nonyne (BCN) conjugate-based drug delivery service
Ac₄ManAz analog-DBCO conjugate-based drug delivery service
We design enzyme-activated Ac₄ManAz analogs based on your research needs and conduct experiments using selective labeling of tumor tissue mediated by histone deacetylases and histones highly expressed in tumors.

Classification of bioreactors. (CD BioGlyco)

Publication Data

Technology: Metabolic engineering

Journal: Nano Today

IF: 18.962

Published: 2022

Results: This literature focuses on designing two types of strategies for bioreactor-based drug delivery. One approach is to utilize the intrinsic conditions of the organism (disease site or cell-specific environment) to drive biotransformation, such as bioorthogonal chemistry (the coupling of glucose metabolic engineering and bioorthogonal reactions can facilitate tight binding between the targeting agent and the labeled cells, thus enhancing the efficiency of drug delivery to the target site. Another approach is to utilize living organisms as templates/response sites for biotransformation in response to external stimuli, which may occur in tissues, cell surfaces, intracellular, cellular vesicles, or organelles/proteins.

Fig.1 Potential uses for bioreactor-based drug delivery systems Fig.1 Application of bioreactor-based drug delivery system. (Yang, et al., 2022)

Applications

Bioreactors provide microenvironments that mimic those found in the human body for drug screening and efficacy assessment. Bioreactors are used to simulate the in vivo environment, and the effects of drugs can be more accurately assessed at the cellular and tissue levels, accelerating the process of new drug development.
Bioreactors can simulate various disease models, such as tumor models, infection models, etc., for research on disease mechanisms and evaluation of drug effects.
Bioreactors are utilized for the development of drug delivery systems, such as nanocarriers and microcapsules, enabling precise administration of drugs to specific tissues or cells.

Advantages

Bioreactors offer precise control over drug delivery, encompassing the rate, timing, and site of drug release. This facilitates the attainment of targeted, quantitative, and sustained drug administration.
Bioreactor-based drug delivery provides a well-protected environment to avoid contamination and degradation of drugs from the external environment. This helps to improve the stability of the drug and prolong the effective life of the drug.
By precisely controlling drug delivery and targeting therapies, bioreactors allow for low-dose drug delivery and reduced toxicity.

Over several years, CD BioGlyco has consistently delivered exceptional results based on the innovative GlycoCLICK™ technology. Our cutting-edge bioreactor-based drug delivery services offer a more efficient and streamlined approach to drug discovery and development. For further details, please don't hesitate to contact us.

Reference

Yang, C.; et al. Bioreactor: Intelligent platform for drug delivery. Nano Today. 2022, 44: 101481.

For research use only. Not intended for any clinical use.

Related Services